NTRA
Natera
$44,762.42 Mn
311.69
-0.79%
+93.42%
Natera operates as a diagnostics company that provides clinical laboratory and genetic testing services, generating the vast majority of its revenue from processing millions of tests. Its business model involves performing molecular and bioinformatics analysis on patient samples for oncology, women's health, and organ health, billing for these diagnostic-testing services.
IDXX
2nd
Idexx Laboratories
$43,642.56 Mn
553.32
+1.32%
-13.25%
The company operates outside reference laboratory services, providing diagnostic and consulting services to veterinary clinics and producers.
DGX
Quest Diagnostics
$26,076.81 Mn
236.26
+0.32%
+32.03%
Quest Diagnostics provides clinical laboratory and diagnostic testing services, generating revenue primarily from fees charged for laboratory testing. The company offers a broad menu of routine and specialty tests in areas such as cardiology, oncology, and genetics.
LH
Labcorp Holdings
$26,065.98 Mn
322.20
-0.37%
+19.12%
Labcorp's Diagnostics Laboratories segment performs over 750 million tests annually, providing clinical, genetic, and anatomic pathology services to physicians, hospitals, and patients. This core activity of running tests on patient samples and billing payers per test aligns directly with the Diagnostic Labs classification.
GH
Guardant Health
$21,394.06 Mn
160.12
-0.96%
+169.24%
Guardant Health operates clinical laboratories and generates revenue primarily from providing diagnostic testing services, such as the Guardant360 CDx and Shield tests, to healthcare providers and hospitals. The company bills payers and patients for these clinical laboratory services.
EXAS
Exact Sciences
$20,017.07 Mn
104.91
+0.95%
+136.92%
Exact Sciences provides clinical diagnostic and laboratory testing services, specifically for cancer screening and precision oncology. The company generates revenue by delivering test results for products like Cologuard Plus, Cancerguard, and Oncotype DX to patients and healthcare providers.
ICLR
2nd
Icon
$12,888.61 Mn
167.05
-1.42%
-6.45%
The company operates a Laboratory Services segment that delivers high-value clinical testing services, including bioanalytical, biomarker, and central laboratory capabilities for vaccine development and oncology research.
DVA
2nd
Davita
$11,373.12 Mn
177.83
+0.67%
+33.46%
The company operates laboratory services that provide routine testing for dialysis adequacy and mineral metabolism to support clinical decision making, billing for these diagnostic tests.
HIMS
2nd
Hims & Hers Health
$6,392.36 Mn
27.40
-4.26%
-39.25%
The company provides laboratory testing services that offer biomarker measurements for health assessment and clinical management.
CAI
Caris Life Sciences
$5,925.76 Mn
20.97
-3.05%
-41.67%
Caris Life Sciences generates primary revenue from selling molecular profiling tests, including tissue and blood-based genomic profiling (MI Profile, Caris Assure), to physicians and hospitals. This activity constitutes providing clinical laboratory and diagnostic testing services for cancer detection and treatment monitoring.
SHC
Sotera Health
$5,282.29 Mn
18.51
-1.54%
+17.15%
The company operates Nelson Labs, which provides outsourced microbiological and analytical chemistry testing, as well as routine sterility and quality control testing for medical device and pharmaceutical customers.
BLLN
BillionToOne
$4,120.27 Mn
87.99
-6.30%
—
BillionToOne provides clinical molecular diagnostic testing services, specifically prenatal and oncology tests, and generates revenue from reimbursement by insurance, government programs, and patients. Its core business is performing these tests (e.g., UNITY suite and Northstar Select) on patient samples rather than selling the diagnostic machines themselves.
ADPT
Adaptive Biotechnologies
$3,906.50 Mn
24.56
-0.85%
+97.90%
The company generates significant revenue through clinical diagnostic testing, specifically its FDA-authorized clonoSEQ assay used by clinicians, hospitals, and cancer centers for minimal residual disease detection in lymphoid malignancies.
IRTC
iRhythm Holdings
$3,796.47 Mn
115.24
-1.44%
-27.03%
iRhythm generates the majority of its revenue from providing ambulatory cardiac monitoring services through its own Medicare-enrolled independent diagnostic testing facilities. The company collects ECG data, processes it using proprietary software, and delivers diagnostic reports to physicians, billing third-party payers per monitoring episode.
VCYT
Veracyte
$3,269.20 Mn
40.68
-3.33%
+35.28%
Veracyte operates CLIA certified laboratories in South San Francisco, San Diego, and Austin to perform laboratory developed tests such as Afirma and Decipher Prostate. The majority of its revenue is generated from these diagnostic-testing service fees paid by Medicare and private commercial payers.
GRAL
Grail
$3,166.39 Mn
70.89
+1.34%
+116.13%
GRAIL provides clinical diagnostic testing services through its Galleri blood-based test, which is sold to employers, health systems, and payors. The company operates a high-capacity laboratory capable of processing up to one million tests per year to provide these diagnostic results.
NEOG
2nd
Neogen
$2,518.79 Mn
11.57
-2.53%
+108.84%
The company provides standalone genomics testing services to breed associations, universities, and commercial laboratories worldwide.
CDNA
CareDx
$2,377.46 Mn
46.18
-0.43%
+289.70%
CareDx generates significant revenue from providing clinical diagnostic testing services, such as AlloSure Kidney and AlloMap Heart, which are performed in its Brisbane, California laboratory and reimbursed by Medicare and private payers.
WGS
GeneDx Holdings
$2,275.17 Mn
76.34
-1.36%
-39.36%
GeneDx generates its primary revenue from the sale of diagnostic test reports for exome and genome sequencing, such as ExomeDx and GenomeDx. The company operates CLIA-certified high-complexity laboratories to provide these clinical laboratory and genetic testing services to hospitals, clinics, and clinicians.
NEO
Neogenomics
$2,033.90 Mn
15.90
-1.61%
+154.81%
NeoGenomics operates a network of cancer-focused testing laboratories providing clinical oncology diagnostic testing, including molecular and NGS testing. Its revenue is generated through diagnostic-testing service fees for services like cytogenetics, FISH, and flow cytometry sold to healthcare providers and hospitals.
PSNL
Personalis
$1,479.57 Mn
13.91
+0.14%
+186.80%
Personalis provides clinical laboratory and diagnostic testing services, specifically cancer genomic testing, through its CLIA-certified and CAP-accredited high-complexity laboratory. Its revenue is generated from performing tests such as NeXT Personal Dx and NeXT Dx for pharmaceutical companies, diagnostic partners, and cancer patients.
AZTA
2nd
Azenta
$1,443.36 Mn
32.98
-1.79%
+8.42%
The Multiomics segment provides clinical and research diagnostic services, specifically gene sequencing (Next Generation and Sanger), gene synthesis, and bioinformatics services.
OPK
2nd
Opko Health
$1,015.01 Mn
1.36
+0.00%
-2.86%
Through its BioReference subsidiary, the company operates clinical laboratory operations providing routine and specialized diagnostic testing services, including the proprietary 4Kscore prostate cancer test.
CSTL
Castle Biosciences
$885.66 Mn
29.03
-3.07%
+41.20%
Castle Biosciences operates as a molecular diagnostics company that provides clinical laboratory testing services, such as DecisionDx-Melanoma and TissueCypher, to clinicians. Its revenue is generated from diagnostic-testing service fees billed to third-party payors, Medicare, and patients.
FLGT
Fulgent Genetics
$510.95 Mn
18.57
-0.48%
-13.71%
Fulgent Genetics operates a laboratory services business that performs anatomic pathology and molecular diagnostics, generating the majority of its revenue from fees charged for laboratory tests performed for hospitals, reference labs, and institutional clients.
DNA
2nd
Ginkgo Bioworks Holdings
$415.40 Mn
6.52
-5.78%
-52.75%
Through its Biosecurity segment, specifically the Canopy and Horizon offerings, the company provides genomic surveillance, pathogen detection, and biomonitoring services to government customers.
YDES
2nd
YD Bio
$281.74 Mn
3.98
+18.10%
-65.98%
The company creates noninvasive diagnostic tests analyzing cfDNA methylation patterns to detect pancreatic and breast cancers, which are offered as laboratory developed tests to licensed health care providers.
MYGN
Myriad Genetics
$274.37 Mn
2.87
-5.90%
-49.74%
Myriad Genetics operates as a molecular diagnostics company that provides clinical laboratory testing services, such as the GeneSight test for mental health and MyRisk for hereditary cancer. Its revenue is derived from performing these diagnostic tests on patient samples and billing healthcare providers and patients.
BDSX
Biodesix
$235.68 Mn
22.34
-3.91%
+162.82%
Biodesix operates as a diagnostic solutions company that provides blood-based tests, such as Nodify CDT and VeriStrat, to healthcare providers for lung cancer risk assessment and treatment guidance. Its primary revenue source is Lung Diagnostic Testing, which bills for the performance of these clinical tests on patient samples.
SEER
2nd
Seer
$223.97 Mn
2.02
-0.49%
-1.46%
Through its Seer Technology Access Centers (STACs), the company provides fee-for-service access to its proteomic workflow, delivering diagnostic-grade data to researchers on a pay-per-use basis.
AGPU
2nd
Axe Compute
$218.84 Mn
10.33
-2.73%
-19.28%
The company operates a clinical testing division that provides CLIA certified services, including Tumor Drug Response Testing and Genomic Profiling, to physicians and cancer patients.
LUCD
Lucid Diagnostics
$188.85 Mn
0.99
+1.02%
-2.94%
Lucid Diagnostics operates a CLIA certified laboratory through its subsidiary LucidDx Labs that performs the EsoGuard assay. The company generates revenue by billing Medicare, private insurers, and patients for each diagnostic test performed on patient samples.
XGN
Exagen
$159.43 Mn
6.59
-1.64%
-32.41%
Exagen operates a CLIA-certified and CAP-accredited laboratory in Vista, California, where it performs high-complexity diagnostic testing for autoimmune diseases. Its revenue is primarily generated from providing these clinical laboratory services, specifically through its AVISE® CTD and AVISE® Lupus tests, which are billed to insurers, Medicare, and Medicaid.
IMDX
2nd
Insight Molecular Diagnostics
$139.63 Mn
4.28
+0.23%
+60.30%
The company operates a CLIA certified facility in Franklin, Tennessee, where it performs the GraftAssureCore laboratory developed test as a service for customers.
QTRX
2nd
Quanterix
$126.32 Mn
2.68
-8.22%
-45.86%
The company operates a CLIA certified Accelerator Laboratory that provides clinical laboratory testing services and LDTs, such as LucentAD Complete and Simoa NfL, to hospital networks and reference labs.
SERA
Sera Prognostics
$97.42 Mn
1.93
-1.03%
-18.91%
Sera Prognostics provides clinical diagnostic testing services through its PreTRM blood-based biomarker test. The company generates revenue from the administration of these tests to patients, with payments coming from healthcare providers and reimbursement from insurers like Elevance Health.
BNR
Burning Rock Biotech
$87.87 Mn
10.00
+9.89%
-1.67%
Burning Rock Biotech operates a central laboratory model where it processes tissue and liquid biopsy samples from partner hospitals and issues diagnostic reports. Its primary revenue is derived from providing these next-generation sequencing-based cancer therapy selection and early detection testing services.
PRPO
Precipio
$43.97 Mn
24.69
+3.31%
+72.66%
Precipio operates two full-service laboratories that provide specialized cancer diagnostic testing, including molecular diagnostics and cytogenetics, to physicians and hospitals. This division generates recurring service revenue reimbursed by Medicare, Medicaid, and private insurers.
MDXH
MDxHealth
$38.52 Mn
0.75
-12.79%
-74.83%
MDxHealth operates a CLIA accredited CAP certified laboratory network to provide clinical diagnostic testing services. It generates revenue by performing tests such as Confirm mdx, GPS mdx, and Exo mdx on patient samples and delivering results to urology clinics and pathology laboratories.
CCEL
Cryo Cell International
$31.61 Mn
3.92
-1.75%
-7.33%
The company's core business is the collection, processing, testing, and long-term cryogenic storage of umbilical cord blood and tissue stem cells. These activities constitute clinical laboratory and diagnostic testing services, with revenue generated from processing and storage fees.
PSTV
2nd
Cerenome
$26.35 Mn
3.84
+1.86%
-79.76%
The company operates a CLIA certified laboratory through its subsidiary CNSide Diagnostics LLC, which provides clinical diagnostic testing services via the CNSide Cerebrospinal Fluid Tumor Cell Enumeration test. It generates current revenue from these laboratory-developed tests reimbursed by payers like UnitedHealthcare and Humana.
BNGO
2nd
Bionano Genomics
$13.90 Mn
1.18
-0.84%
-62.54%
The company operates Bionano Laboratories, which provides diagnostic testing services to clinicians and hospital genetics departments.
TEM
Tempus AI
$8.88 Mn
49.36
-4.42%
-37.08%
Tempus AI operates a laboratory network that performs genomic and molecular testing, including next-generation sequencing and PCR, for oncology and cardiology patients. It generates primary revenue by providing these diagnostic testing services to hospitals, physicians, and other healthcare providers.
CDIO
2nd
Cardio Diagnostics Holdings
$5.65 Mn
1.91
-4.02%
-48.66%
The company operates its own CLIA certified high complexity testing laboratory to provide laboratory services for its diagnostic tests.
AIDX
20
$3.98 Mn
0.52
-5.45%
—
The company operates a CAP accredited CLIA licensed laboratory and generates the majority of its revenue from providing clinical diagnostic blood tests, specifically the OneTest for Cancer and OneTest for Longevity. It bills for these diagnostic-testing services provided to consumers, employers, and retail clinics.
ACUT
Accustem Sciences
$3.86 Mn
0.24
+50.00%
-86.59%
AccuStem Sciences provides clinical diagnostic testing services, specifically genomic tests for cancer care such as the MSC test for lung nodules and the StemPrintER test for breast cancer. Its revenue model is based on reimbursement from insurers and payments from healthcare providers for performing these diagnostic tests.
BGLC
2nd
BioNexus Gene Lab
$2.90 Mn
1.56
-1.89%
-70.68%
Through MRNA Scientific, the company operates laboratories in Kuala Lumpur and Penang that provide clinical diagnostic testing services. It earns fees for conducting blood sample analyses to detect RNA biomarkers for diseases such as cancer and cardiovascular risks, serving hospitals, clinics, and corporate clients.
BIAF
bioAffinity Technologies
$2.46 Mn
0.47
+20.51%
-93.61%
The company generates its primary revenue through the sale of CyPath® Lung tests, which are performed by its wholly owned subsidiary PPLS, a CLIA-certified clinical laboratory. It provides diagnostic and lab-testing services to physicians to detect early-stage lung cancer.
INBS
2nd
Intelligent Bio Solutions
$1.70 Mn
3.22
-4.45%
-78.53%
The company generates additional revenue from confirmatory testing services where samples are sent to third party laboratories for analysis.
LUDG
Ludwig Enterprises
$1.67 Mn
0.01
-50.00%
-87.50%
Ludwig Enterprises generates revenue through laboratory analysis services for its Laboratory Developed Tests, such as the Revealia™ Breast test. The company provides clinical diagnostic testing services using mRNA biomarkers to detect inflammation-related chronic diseases and cancers.
NIVF
2nd
NewGenIvf
$0.01 Mn
0.55
-9.84%
-99.52%
The company provides preimplantation genetic testing and genetic screening tools as part of its treatment offerings to enhance outcomes for patients.
ADTX
2nd
Aditxt
$0.00 Mn
0.00
—
-100.00%
The company operates a high-complexity CLIA CAP accredited laboratory in Richmond Virginia to support assay development and has licensed antibody testing to other CLIA CAP certified laboratories.
